Deep brain stimulation (DBS) has shown promise as a treatment for some symptoms of Parkinson s disease (PD). However, not all symptoms improve equally well with DBS. A better understanding of how ...

In patients with advanced Parkinson's disease (PD), quality of life (QoL) remains stable at 5 years in those who receive deep brain stimulation of the subthalamic nucleus (STN-DBS) vs standard-of-care ...

Researchers from Mass General Brigham identified therapeutic targets that may optimize symptom-specific treatment for Parkinson’s disease. Brain circuits associated with symptom improvements of tremor ...

While DBS has been linked with positive outcomes in patients with PD, its efficacy in patients with GBA mutations (GBA-PD) is less clear. This retrospective, multicenter study included 365 people with ...

Please provide your email address to receive an email when new articles are posted on . The adaptive deep brain stimulation technology is the first of its kind to address symptoms of Parkinson’s ...

A new study led by Bucknell University Professor Karlo Malaga, biomedical engineering, has identified key insights into optimizing deep brain stimulation (DBS) for Parkinson's disease patients.

A new study published in JAMA Network Open Neurology reports on a five-year follow-up of Parkinson disease (PD) patients treated with either medication alone or deep brain stimulation (DBS) of the ...

Shortly after obtaining a greenlight in Europe and after more than 10 years in development, Medtronic has now received the FDA’s approval for its adaptive, closed-loop neurostimulation approach to ...

Parkinson's disease (PD) is the second most common neurodegenerative disorder, primarily characterized by motor dysfunction. Its pathological hallmark is the abnormal aggregation of α-synuclein (α-syn ...

Medtronic (NYSE:MDT) has won FDA approval for a deep brain stimulation system for Parkinson’s disease. The approval is for BrainSense Adaptive deep brain stimulation (DBS)and BrainSense Electrode ...